CYRAMZA (ramucirumab) is a recombinant human IgG1 monoclonal antibody that specifically binds to vascular endothelial growth factor receptor 2. ramucirumab has an approximate molecular weight of 147 kDa. ramucirumab is produced in genetically engineered mammalian CHO cells.
Ramucirumab is supplied at a concentration of 10 mg/mL as a sterile, preservative-free, clear to slightly opalescent and colorless to slightly yellow solution of pH 6.0, which contains 9.98 mg/mL glycine, 0.65 mg/mL histidine, 1.22 mg/mL histidine monohydrochloride, 0.1 mg/mL polysorbate 80, 4.383 mg/mL sodium chloride, and Water for Injection.
|
Name
|
Ramucirumab
|
|
CAS NO.
|
947687-13-0
|
|
Type
|
Whole antibody
|
|
Source
|
Human
|
|
Target
|
VEGFR2 (KDR)
|
|
Clone
|
Monoclone
|
|
Molecular Weight
|
147 kDa
|
|
Formula
|
C6374H9864N1692O1996S46
|
|
Antibody Form
|
Purified immunoglobulin
|
|
Physical Form
|
Solution
|
|
Grade Standard
|
Medicine Grade
|
|
Place of Origin
|
China (Mainland)
|
|
Storage
|
-70±15℃ for long-term storage, 2-8℃ for short-term storage, away from light.
|
bio-equip.cn
Shanghai Topwell Pharma Co., Ltd. is specialized in research, development, custom manufacturing and sales of Pharmaceutical Intermediates, APIs, Pharmaceutical Excipients, Health & Nutritional Ingredients, Polypeptides and Antibodies, etc..
Topwell has a professional R&D team. We have built close cooperative relationships with many research institutes and universities in China. In addition, we have very close cooperation relationships with many Chinese pharmaceutical factories.
Topwell aims to become a global leader in pharmaceutical & chemical industry.
中文
